NVIDIA and Eli Lilly announced a five‑year, $1 billion collaboration to create a Co‑Innovation AI Lab focused on accelerating AI applications in drug discovery and development. The partnership will combine NVIDIA’s accelerated computing and Lilly’s drug development expertise to scale models and computational infrastructure. At a JPM fireside chat, NVIDIA CEO Jensen Huang and Lilly CEO David Ricks framed the lab as an effort to co‑design software and hardware stacks for large biomedical models. The initiative will target target validation, generative biology workflows, and model deployment across the pharma discovery pipeline. The tie‑up reflects how major tech vendors and big pharmas are formalizing multi‑year investments to operationalize AI in R&D. The lab aims to reduce compute bottlenecks in training foundation models and to build validated workflows for translational teams.